Search
Memantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalIn 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. … Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD).
Categories: N-methyl-D-aspartate Receptor AntagonistValoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States.
Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. … It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).
International brands: Sheng AoEfanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalEndogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]
Capsicum oleoresin
go.drugbank.com/drugs/DB11131ApprovedDue to its analgesic properties, capsicum oleoresin is used to temporarily relieve of minor aches and pains of muscles and joints as an active ingredient in topical OTC preparations and has been studied
Mixtures: Herbalax Forte No 70 Tab, HO YAN HOR MEDICATED OILEsomeprazole
go.drugbank.com/drugs/DB00736ApprovedInvestigational[A177577, A177580] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. … Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme
Categories: Antiinflammatory and Antirheumatic Products, Non-SteroidsTrimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigational[A233215] It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate … [A233255,A233260] Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response to myocardial ischemia, activate sodium-hydrogen and sodium-calcium antiport systems.
Haloprogin
go.drugbank.com/drugs/DB00793ApprovedWithdrawnHaloprogin is no longer available in the United States and has been discontinued. … The mechanism of action is unknown, but it is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function.
Fexinidazole
go.drugbank.com/drugs/DB12265Approved[A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by _T. brucei gambiense_ and _T. brucei rhodesiense_, remains a moderate risk (>1/10,000 inhabitants per
Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176606] Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be